Showing results (1151-1160 of 1,193) with videos related to

Sort By:
Pageof 120
Research Square|March 3, 2023
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analysesMarina Konopleva, Courtney DiNardo, Tushar Bhagat, et al.
Blood|February 1, 2023
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromesAmer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, et al.
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Nature Genetics|July 2, 2025
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantationHidetaka Uryu, Koichi Saeki, Hiroshi Haeno, et al.
Nature Communications|April 11, 2025
Natural killer cells' functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromesJuan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, Bijender Kumar, et al.
The Lancet. Haematology|September 8, 2020
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, et al.
Blood Cancer Discovery|May 9, 2022
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell LymphomaNeeraj Y Saini, David M Swoboda, Uri Greenbaum, et al.
The Lancet. Oncology|November 11, 2023
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective studyQinghe Zeng, Christophe Klein, Stefano Caruso, et al.
Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Pageof 120